Superiority of ArTiMist Versus Quinine in Children With Severe Malaria

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

151 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by \>= 90% within 24 hours after the start of treatment in children with severe malaria, or uncomplicated malaria with gastrointestinal complications

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of ArTiMist™ in Children

NCT01047436

Falciparum Malaria

COMPLETED PHASE2

Randomized Trial on Effectiveness of ACTs in Ghana

NCT00374205

Malaria, Falciparum

TERMINATED PHASE4

Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study

NCT06472258

Malaria

COMPLETED NA

Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

NCT00406146

Uncomplicated Malaria

UNKNOWN PHASE3

Phase II Artesunate Study in Severe Malaria

NCT00522132

Malaria

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malaria causes significant morbidity and mortality in children in developing countries, despite the availability of highly effective antimalarial therapy. One of the key contributing factors is the delay in the initiation of treatment.

ArTiMist is a sublingual formulation of the established antimalarial treatment, artemether. In previous studies good bioavailability has been demonstrated. In an exploratory study (ART003) ArTiMist demonstrated a non statistically significant improvement of 26% (when compared to intravenous quinine) in the numbers of patients experiencing a parasite reduction of \>= 90% within 24 hours of the initiation of treatment.

This Phase 3 study is being conducted to establish whether treatment with ArTiMist in children with severe falciparum malaria or uncomplicated falciparum malaria with gastrointestinal complications is at least 20% superior in providing parasitological success (defined as \>= 90% reduction in parasite count at 24 hours after start of treatment) when compared to intravenous quinine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasmodium Falciparum Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ArTiMist

Group Type EXPERIMENTAL

Artemether Sublingual Spray

Intervention Type DRUG

Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints

Quinine

Group Type ACTIVE_COMPARATOR

Quinine

Intervention Type DRUG

Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artemether Sublingual Spray

Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints

Intervention Type DRUG

Quinine

Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ArTiMist

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial
2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive
3. The patient has falciparum malaria as evidenced by thick or thin blood smears of ≥ 500 P Falciparum per mcl (patients with mixed infections may be included provided ≥ 500 P Falciparum per mcl)
4. The patient has either:

* severe or complicated falciparum malaria as determined by the investigator based on the WHO criteria for severity, and/or
* uncomplicated falciparum malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.

Exclusion Criteria

1. The patient's legally acceptable representative does not provide informed consent for participation, or the child if capable, does not assent to participation in the trial.
2. Ability to tolerate oral therapy
3. Patient has received any antimalarial therapy within the 7 days prior to first study drug administration.
4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).
5. Patient has a contraindication, allergy or is otherwise intolerant to either artemether or quinine .

Eligible Sex

ALL

Accepts Healthy Volunteers

No